INTRODUCTION {#s1}
============

Whole-pelvic radiotherapy (WPRT) is theoretically a valid option for treatment of high-risk prostate cancer, given the potential risk of lymph node metastasis \[[@RRU086C1], [@RRU086C2]\]. However, its significance remains unclear because its effect on survival rate has not yet been clarified. The Radiation Therapy Oncology Group (RTOG) 9413 trial demonstrated improved progression-free survival (PFS) for high-risk prostate cancer patients treated with WPRT compared with prostate-only RT (PORT) \[[@RRU086C3]\]. The updated analysis of RTOG 9413 continued to show an advantage of WPRT with neoadjuvant hormone therapy with regards to prostate-specific antigen (PSA) control and PFS at 10 years \[[@RRU086C4]\]. On the other hand, the GETUG-01 trial, from the Groupe D\'Etude des Tumeurs UroGenitales, showed no difference in PFS and overall survival between WPRT and PORT \[[@RRU086C5]\]. However, the GETUG-01 trial included only 45% of patients with a risk of lymph node (LN) involvement \>15%, and their field sizes were smaller than those defined in the RTOG 9413 trial.

Several randomized controlled trials have demonstrated that escalation of radiation dose beyond 70 Gy improves PSA control \[[@RRU086C6], [@RRU086C7]\]. In contrast, WPRT results in an increased dose to the organs at risk (OARs) and therefore the prostate dose is generally restricted to ∼70 Gy with conventional RT \[[@RRU086C3], [@RRU086C5], [@RRU086C8]--[@RRU086C10]\]. Given this background, intensity-modulated radiotherapy (IMRT) has been used at some facilities in the context of dose escalation to the prostate with prophylactic WPRT. Planning studies comparing IMRT with conventional radiation techniques for WPRT have shown that IMRT provides superior OAR sparing \[[@RRU086C11]\] and target coverage \[[@RRU086C12]\]. In addition, early clinical results confirmed the potential of WP-IMRT with acceptable rates of acute toxicity \[[@RRU086C13]--[@RRU086C17]\]. Furthermore, a recently reported study demonstrated that adding an image-guided (IG) technique to WP-IMRT results in lower acute rectal and bladder toxicities \[[@RRU086C18]\].

Volumetric-modulated arc therapy (VMAT) is a relatively new rotational radiation therapy technique based on the idea of delivering IMRT with continuous dynamic modulation of the dose rate, field aperture, and gantry speed. Although planning studies on dosimetric comparison in the prostate only or in the prostate with seminal vesicles found that VMAT achieved equal or better target coverage and normal tissue sparing over IMRT \[[@RRU086C19]--[@RRU086C22]\], planning studies that have been focused on larger and more irregularly shaped pelvic target volumes, including the prostate, seminal vesicles, and pelvic lymph nodes, have shown inconsistent dosimetric results \[[@RRU086C23]--[@RRU086C26]\]. The report of Pesce *et al*. \[[@RRU086C27]\] is one of the limited studies reporting the toxicity of VMAT in the treatment of prostate cancer; however, this study was designed to evaluate PO-VMAT, not WP-VMAT. Thus, there remain several areas to be clarified in WP-VMAT.

The current study was undertaken in order to evaluate dosimetric quality and acute toxicity of WP-VMAT and image-guided RT (IGRT) in 100 consecutive patients with high-risk prostate cancer.

MATERIALS AND METHODS {#s2}
=====================

Patients {#s2a}
--------

This analysis is based on the first 100 high-risk prostate cancer patients treated with WP-VMAT with daily image-guidance between July 2011 and December 2013. High-risk was defined as cT3/4 N0 M0 and/or a Gleason score of 8, 9 or 10 and/or a pretreatment PSA concentration of ≥20 ng/ml. Relevant patient characteristics are shown in Table [1](#RRU086TB1){ref-type="table"}. Of the 100 patients, 96 received androgen deprivation therapy (ADT), which typically started 3--6 months before RT and continued for a total duration of ≥24 months. Written informed consent was obtained from all patients, and the institutional ethics committee approved the study. Table 1.Patient characteristics (*n* = 100)CharacteristicValueAge (y) Median72 Range53--79Gleason score 5--65 728 8--1067PSA (ng/ml) Median28.4 Range4.8--445.0Clinical stage T112 T230 T352 T46Diabetes (%)17Anticoagulants (%)17Androgen deprivation (%)96[^1]

Simulation, organ contouring, and planning {#s2b}
------------------------------------------

Computed tomography (CT) was acquired in the supine position, with 1.25-mm thick slices from the upper abdomen to 5 cm below the ischial tuberosities after immobilization with a vacuum-based device (VacLoc^TM^, CIVCO Medical Solutions, Kalona, IA). The patients were instructed to have a comfortably filled bladder and an empty rectum at CT acquisition and for each treatment. The CT data set was transferred to the Eclipse ver. 10.0 treatment planning system (Varian Medical Systems, Palo Alto, CA). The prostate clinical target volume (CTV) was defined as the entire prostate with an area 1.5 cm proximal to the seminal vesicles, and any visible tumor extension. The prostate planning target volume (PTV) was generated by adding an 8-mm margin to the prostate CTV in all dimensions, except posteriorly, where a 5-mm margin was used. Pelvic lymph node volumes were standardized based on the consensus recommendations of the RTOG \[[@RRU086C28]\]. The nodal CTV consisted of a 0.7-cm expansion volume on the obturator vessels in addition to the common, external and internal iliac vessels, while excluding adjacent bone, muscle, bowel and bladder. The nodal CTV commenced at the L5 to S1 interspace, with the external iliac nodal volumes stopping at the top of the femoral head and the obturator nodal volumes stopping at the top of pubic symphysis. Differing from the RTOG consensus, the presacral nodes were not included in the nodal CTV. The nodal PTV was defined by a 0.5-cm expansion of the nodal CTV. Contouring of the OAR was defined according to the RTOG pelvic normal tissue contouring guidelines \[[@RRU086C29]\]. The OAR were contoured and considered as solid organs. The rectum was segmented from the level of the ischial tuberosities to the rectosigmoid flexure, and the entire bladder was contoured from its apex to the dome. The femoral heads were delineated to the level of the ischial tuberosities. The bowel bag was contoured as the entire volume of peritoneal space to within 1 cm of the cranial margin of the nodal PTV.

Treatment was prescribed such that the prostate PTV received 78 Gy in 39 fractions, while the nodal PTV received 46.8 Gy in 26 fractions, by use of 10-MV photons. In all cases, dose normalization was set to the mean dose to the prostate PTV, while keeping the mean dose to the nodal PTV as close to 46.8 Gy as possible. The VMAT plan was given in two phases. In the first phase, the nodal PTV and the prostate PTV received 46.8 Gy and 52 Gy, respectively, both in 26 fractions using double-arc VMAT with a simultaneous integrated boost (SIB) technique. In the second phase, the prostate PTV received 26 Gy in 13 fractions using single-arc VMAT. In general, double-arc VMAT can achieve higher conformity and homogeneity compared with a single-arc plan. Owing to the complexity of a WP-VMAT plan and the poor results obtained with single-arc, double-arc was used to optimize the WP-VMAT. Plans were defined as acceptable when ≥95% of the PTV received ≥95% of the prescribed dose. The OAR dose volume constraints were: volume receiving a minimal dose of 70 Gy (V~70Gy~) less than 20% and V~50Gy~ less than 45% for the rectum; and V~70Gy~ less than 25% and V~50Gy~ less than 50% for the bladder. For the femoral heads, the dose objective was minimal dose to 2% (D~2%~) less than 50 Gy. The bowel bag was limited to D~2%~ less than 50 Gy and V~45Gy~ less than 195 ml. The dose calculation was performed using the anisotropic analytic algorithm (AAA, version 10.0.28) and a voxel size of 0.25 × 0.25 × 0.25 cm^3^.

Online image-guided radiotherapy {#s2c}
--------------------------------

Patients were treated with a Novalis Tx treatment unit (Varian Medical Systems, and BrainLAB AG, Feldkirchen, Germany). Daily image guidance with ExacTrac and cone-beam CT (CBCT) was performed in all patients. After the patients were immobilized in the vacuum-based device, the skin marks on the patient were used for initial setup. Orthogonal kilovoltage radiographs of the patients were then obtained using the ExacTrac and registered to the reference digitally reconstructed radiographs generated from the planning CT. Once the bone registration was satisfactory, CBCT images were also obtained and then used to accomplish the target/soft tissue registration.

Dosimetric analysis {#s2d}
-------------------

Dose--volume histograms (DVHs) were constructed for the prostate PTV, nodal PTV, rectum, bladder, femoral heads, and bowel bag in each plan. DVHs were averaged among 100 subjects. Parameters chosen for measuring dosimetric quality of treatments were D~2%~ and D~95%~ for the prostate PTV and mean dose and D~95%~ for the nodal PTV. For the rectum and bladder, the analysis included the mean dose, D~2%~, V~70Gy~, V~50Gy~ and V~30Gy~. D~2%~ of each femoral head and both D~2%~ and V~45Gy~ of bowel bag were also scored. The total number of monitor units (MUs) per fraction and the beam-on time were used to evaluate the efficiency of treatment delivery.

Acute toxicity {#s2e}
--------------

Gastrointestinal (GI) and genitourinary (GU) toxicities were prospectively scored for all patients, using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 adverse event scoring system. Patients were monitored weekly during RT and again at 2 weeks and 3 months after the end of RT. Toxicity occurring within 90 days of the end of RT was classified as acute toxicity. The dosimetric data for those patients experiencing Grade 1 or less acute toxicity associated with each normal structure (rectum, bladder, or bowel bag) was compared with the data for patients with Grade 2 toxicity.

Statistical analysis {#s2f}
--------------------

An unpaired Student\'s *t* test was used to compare mean values of each dose metric after confirming that each dataset was normally distributed (using the Kolmogorov--Smirnov test) and the variances of two datasets to compare were equal (using the F-test). Significance was defined at *P* \< 0.05. All reported *P*-values are two-tailed.

RESULTS {#s3}
=======

All patients completed RT and follow-up for 3 months after RT. No interruption of RT related to acute toxicity was observed.

Representative axial and coronal dose distributions for the composite plans are shown in Fig. [1](#RRU086F1){ref-type="fig"}. The mean value of the dosimetric parameters of the PTVs and the OARs are shown in Table [2](#RRU086TB2){ref-type="table"}. All dose--volume constraints were satisfactorily met for all treatment plans. Figure [2](#RRU086F2){ref-type="fig"} shows the average DVH for the prostate PTV, nodal PTV, rectum, bladder, and bowel bag. Mean MUs and beam-on time were 471 ± 45 and 146 ± 1 s for double-arc VMAT, respectively, and 520 ± 59 and 76 ± 2 s for single-arc VMAT, respectively. Table 2.Dosimetric parameters for PTV and OARParameterValue(mean ± SD)Prostate PTVVolume(ml)92.4 ± 23.0D~2%~(Gy)79.3 ± 0.2D~mean~(Gy)78D~95%~(Gy)76.4 ± 0.3Nodal PTVVolume(ml)774.6 ± 130.6D~mean~(Gy)46.8 ± 0.4D~95%~(Gy)44.8 ± 0.4RectumVolume(ml)61.1 ± 15.8D~mean~(Gy)39.8 ± 2.6D~2%~(Gy)77.1 ± 1.1V~70Gy~(%)11.3 ± 3.5V~50Gy~(%)26.3 ± 4.9V~30Gy~(%)64.4 ± 10.7BladderVolume(ml)193.6 ± 89.8D~mean~(Gy)43.9 ± 4.1D~2%~(Gy)78.0 ± 0.8V~70Gy~(%)11.6 ± 5.7V~50Gy~(%)28.1 ± 11.4V~30Gy~(%)80.5 ± 11.6Left femoral headD~2%~(Gy)43.1 ± 2.9Right femoral headD~2%~(Gy)42.2 ± 2.9Bowel bagD~2%~(Gy)47.2 ± 0.7V~45Gy~(ml)76.7 ± 30.3[^2] Fig. 1.Representative dose distributions for the composite plan. Axial computed tomography (CT) images of the pelvis at the level of the prostate gland (**a**) and the pelvic lymph nodes (**b**). Coronal CT showing the prostate gland and the pelvic lymph nodes (**c**). Prostate planning target volumes (PTVs) are shown in red and nodal PTVs are shown in pink. Dose color wash is from 39 Gy (dark blue) to ∼81 Gy (red). Fig. 2.Average (solid line) and 1 standard deviation (dashed line) dose--volume histograms (DVHs) for the prostate planning target volume (prostate PTV), nodal PTV, rectum, bladder, and bowel bag.

No Grade 3 or higher acute toxicity was observed. Maximal acute toxicity is detailed in Table [3](#RRU086TB3){ref-type="table"}. Acute Grade 2 GI and GU toxicity occurred in 16 patients (16%) and 13 patients (13%), respectively. Despite the use of WPRT, only six patients (6%) experienced acute Grade 2 diarrhea. Urinary frequency was the most frequent acute Grade 2 GU toxicity. Table 3.Maximal acute toxicityToxicityGrade012GI37 (37%)47 (47%)16 (16%) Proctitis73 (73%)15 (15%)12 (12%) Diarrhea47 (47%)47 (47%)6 (6%)GU8 (8%)79 (79%)13 (13%) Frequency16 (16%)72 (72%)12 (12%) Incontinence94 (94%)6 (6%)0 Retention92 (92%)7 (7%)1 (1%) Urinary tract pain70 (70%)30 (30%)0 Urgency60 (60%)40 (40%)0[^3]

Point prevalence of Grade 1--2 and Grade 2 toxicities during RT and at early follow-up (2 weeks and 3 months after the end of RT) are illustrated in Fig. [3](#RRU086F3){ref-type="fig"}a and 3b, respectively. Figure [3](#RRU086F3){ref-type="fig"}b indicates that the highest incidence of acute Grade 2 diarrhea was reached around Week 5 (corresponding to the end of WPRT), whereas the highest incidence of acute Grade 2 proctitis and GU toxicity was reached around Week 8, corresponding to the end of the whole course of RT. Three months after treatment, most acute diarrhea, proctitis, and Grade 2 GU toxicity had resolved, whereas Grade 1 GU toxicity was observed in 30% of patients. Fig. 3.Point prevalence of (**a**) Grade 1--2 toxicity and (**b**) Grade 2 toxicity. The horizontal axis shows the number of weeks from start of radiation therapy. The line is cut between the eighth and tenth weeks because different timescales are applied to the first and the latter periods. GU = genitourinary.

The doses to the rectum, bladder, and bowel bag were compared between patients experiencing Grade 2 toxicity and those experiencing Grade 1 or no toxicity (Table [4](#RRU086TB4){ref-type="table"}). The analysis included the volume, mean dose, D~2%~, V~70Gy~, V~50Gy~ and V~30Gy~ for the rectum and bladder; and D~2%~ and V~45Gy~ for the bowel bag. As a result, no dosimetric values correlated with acute rectal, bladder, or bowel bag toxicity. Table 4.Comparison of rectum, bladder, and bowel bag dose statistics stratified by toxicity gradeParameterGrade 2Grade ≤1*P\**(mean ± SD)(mean ± SD)Rectum Volume(cm^3^)64.5 ± 17.660.6 ± 15.60.52 D~mean~(Gy)38.7 ± 2.539.9 ± 2.60.22 D~2%~(Gy)77.0 ± 1.477.1 ± 1.00.84 V~70Gy~(%)10.9 ± 4.611.4 ± 3.30.44 V~50Gy~(%)25.2 ± 4.226.4 ± 5.00.47 V~30Gy~(%)59.7 ± 8.565.0 ± 11.00.16Bladder Volume(cm^3^)162.8 ± 69.2198.2 ± 92.90.26 D~mean~(Gy)46.1 ± 3.243.6 ± 4.20.07 D~2%~(Gy)78.3 ± 0.778.0 ± 0.80.19 V~70Gy~(%)14.3 ± 6.411.2 ± 5.60.08 V~50Gy~(%)32.5 ± 11.327.4 ± 11.40.13 V~30Gy~(%)82.8 ± 11.080.2 ± 11.70.50Bowel bag D~2%~(Gy)47.9 ± 0.547.2 ± 0.70.22 V~45Gy~(cm^3^)88.0 ± 34.676.0 ± 30.00.37[^4]

DISCUSSION {#s4}
==========

In RT for patients with prostate cancer, VMAT is a relatively new approach \[[@RRU086C19]--[@RRU086C27], [@RRU086C30]\]. To the best of our knowledge, this is the first report of prostate cancer patients treated with WP-VMAT and IGRT. All dose--volume constraints were met satisfactorily for all treatment plans with a short treatment time. Clinical outcomes observed were also promising, with low rates of acute GI and GU toxicity.

In patients with high-risk prostate cancer, the use of WPRT is currently controversial. Whereas the RTOG 9413 trial reported a benefit of WPRT \[[@RRU086C3]\], the GETUG-01 trial showed no difference between PORT and WPRT \[[@RRU086C5]\]. One limitation of these trials is that the total dose administered to the prostate was \< 72 Gy. Therefore, it remains an unsettled question whether WPRT is necessary when high-dose radiation is delivered to the prostate. RTOG has recently launched a larger Phase 3 trial (RTOG 0924) in order to address the question of the impact of WPRT with dose escalation to the prostate on overall survival. Traditionally, WPRT for high-risk prostate cancer is delivered in two consecutive phases: the first phase encompasses the whole pelvis to treat the prostate, seminal vesicles, and PLN at risk, and the second phase boosts the prostate alone. Combining WPRT with hypofractionated prostate radiation using the SIB technique is a new approach that can be used to treat patients with high-risk prostate cancer. However, there is little evidence on the long-term toxicity of this approach and no evidence on efficacy \[[@RRU086C31]\]. Therefore, the present study was designed to maintain the standard dose fractionation and use the two-phase treatment in the design of this study, as well as the RTOG 0924 trial \[[@RRU086C32]\].

IMRT generates concave dose distributions and has the potential to deliver radical doses to the pelvic nodes and prostate gland while reducing the dose to surrounding normal tissues. Several authors have described that WP-IMRT provides superior OAR sparing \[[@RRU086C11]\] and target coverage \[[@RRU086C12]\] over 3D conformal radiotherapy (3D-CRT). The DVH data in the present study demonstrate that VMAT can produce equivalent quality of dose distributions when compared with IMRT as reported in other series (Table [5](#RRU086TB5){ref-type="table"}). In addition, the bowel bag DVH parameters met the Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC) dose recommendations, in which the bowel bag volume receiving \>45 Gy should be \< 195 ml \[[@RRU086C33]\]. Thus, the present study confirms that WP-VMAT is dosimetrically feasible. Table 5.Comparison of bladder and rectum dosimetric parameters between recent studies using dose-escalated IMRT and VMAT for treatment of the whole pelvisStudyTechniquePatients (*n*)Total dose (Gy)/ No. of fractionsBladderRectumProstateWhole pelvisV~70Gy~ (%)V~50Gy~ (%)V~70Gy~ (%)V~50Gy~ (%)Deville *et al*. 2010 \[[@RRU086C36]\]IMRT3079.2/4445/259.344.315.751.0RTOG 0924^a^ \[[@RRU086C32]\]IMRT79.2/4445/2520N/A35N/ACurrent studyVMAT10078/3946.8/2611.628.111.326.3[^5]

A major advantage of VMAT over IMRT originates from the superior delivery efficiency. The decreased treatment time of VMAT has the potential to reduce the effects of intrafractional prostate motion \[[@RRU086C34], [@RRU086C35]\]. Moreover, this time saving could be used to increase patient throughput on a treatment unit, which then provides additional time for on-line image guidance without increasing the overall treatment time. Considering the delivery efficiency as well as the acceptable plan quality of VMAT compared with that of IMRT, VMAT may be the preferred modality for treating high-risk prostate cancer in the context of WPRT.

There are limited data reporting the acute toxicity of WP-IMRT in the setting of dose escalation to the prostate. Additionally, despite several favorable dosimetric studies \[[@RRU086C23], [@RRU086C24], [@RRU086C26]\], clinical outcome data reporting toxicity in prostate cancer patients treated with WP-VMAT in the literature are lacking. The acute toxicity rates reported in the current study compare favorably with those reported in other series that employed WP-IMRT (Table [6](#RRU086TB6){ref-type="table"}). Therefore, it seems reasonable to say that WP-VMAT is a useful and valuable way to treat patients with high-risk prostate cancer. There have been some reports of an association between acute toxicity and development of subsequent late complications \[[@RRU086C37]--[@RRU086C39]\]. Therefore, the acceptably low incidence of acute toxicity in the current study might contribute to the lower frequency and lower severity of late toxicity. In the present study, as also observed by others \[[@RRU086C13], [@RRU086C40], [@RRU086C41]\], no correlation was found between acute GI and GU toxicities and dosimetric parameters. The low dosimetric parameters and low frequencies of the severe acute toxicities may have led to the lack of correlation between toxicity and dosimetric variables. Table 6.Comparison of acute toxicity between recent studies using dose-escalated IMRT and VMAT for treatment of the whole pelvisStudyTechniquePatients (*n*)Total dose (Gy)/ No. of fractionsAcute GI toxicity (%)Acute GU toxicity (%)ProstateWhole pelvisGrade 2Grade 3Grade 2Grade 3Sanguineti *et al*. 2008 \[14\]IMRT8776/3854/3043.75.743.78Bayley *et al*. 2010 \[17\]IMRT10379.8/4255.1/2931.11.943.72.9Deville *et al*. 2010 \[36\]IMRT3079.2/4445/25500503Current studyVMAT10078/3946.8/26160130[^6]

IGRT is becoming increasingly popular in combination with IMRT. In this study, daily image guidance with ExacTrac and CBCT was practiced in all patients. WPRT by IG-IMRT is challenging because the pelvic nodes move independently of the prostate. Ferjani *et al.* \[[@RRU086C42]\] demonstrated that for the concurrent treatment of the prostate and PLN, with a planning margin to the prostate of 6--8 mm posterior and a planning margin of 5 mm to the PLN, aligning to the prostate soft tissue on daily CBCT was an effective strategy, and aligning to the pelvic bone would result in underdosing to the prostate in one-third of fractions. The results of Ferjani *et al.* justify the present IG methods and planning margins. Further, IGRT has been shown to be associated with reductions in toxicity. Chung *et al.* \[[@RRU086C18]\] reported that whole-pelvic IG-IMRT permits the use of smaller margins and corresponding lower acute bladder and rectal toxicities compared with IMRT in prostate cancer patients. Although the current study performed IG-VMAT using daily CBCT-based soft tissue registration without intraprostatic fiducial markers (FMs), the incidence of acute toxicity were comparable with those of the Chung *et al*. \[[@RRU086C18]\], who reported that acute Grade 2 proctitis and GU toxicity were both 13% with IG-IMRT using daily target localization with intraprostatic FMs. In addition, Zelefsky *et al.* \[[@RRU086C43]\] have reported that the enhanced accuracy associated with IGRT for the treatment of prostate cancer results in a significant reduction in late urinary toxicity. These data suggest that the use of daily IGRT contributed to the low incidence of acute toxicity in the current study.

The present study has some limitations. First, ADT was not prescribed uniformly. However, 96% of patients received long-term ADT. Second, the follow-up period is still short; hence long-term toxicity has not yet been determined. Although a lower incidence of acute toxicity may decrease the development of subsequent late toxicity, it is possible that WPRT has the potential for worse late toxicity because of the larger field size compared with PORT. Therefore, longer follow-up for assessment of late toxicity is needed.

In conclusion, the present study demonstrated that VMAT provided feasible PTV coverage and OAR sparing with short treatment time in 100 patients. Acute GI and GU toxicity was acceptably low. These findings support the use of VMAT with daily CBCT to deliver WPRT in high-risk prostate cancer. Further study is needed to assess late toxicity and disease control.
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An analysis of results for the first 51 consecutive patients ('A treatment planning and acute toxicity of VMAT in the treatment of high-risk prostate cancer with whole pelvic radiotherapy') was presented at ASTRO\'s 55th Annual Meeting, Atlanta, 22--25 September 2013. The results for the first 100 patients ('A treatment planning and acute toxicity of whole-pelvis volumetric-modulated arc therapy in the first 100 consecutive patients with high-risk prostate cancer') was presented at JRS\'s 73th Annual Meeting, Yokohama, 10--13 April 2014.

[^1]: PSA = prostate-specific antigen.

[^2]: PTV = planning target volume, OAR = organ at risk, D*~n~*~%~ = minimal dose to *n*% of the structure, V*~n~*~Gy~ = absolute or percentage structure volume receiving ≥ *n* Gy.

[^3]: GI = gastrointestinal, GU = genitourinary.

[^4]: D*~n~*~%~ = minimal dose to *n*% of the structure, V*~n~*~Gy~ = percentage or absolute structure volume receiving ≥ *n* Gy. Asterisk indicates unpaired Student\'s *t* test

[^5]: IMRT = intensity-modulated radiotherapy, VMAT = volumetric-modulated arc therapy, V*~n~*~Gy~ = percentage structure volume receiving ≥*n* Gy, N/A = not applicable. ^a^Dose constraints used in RTOG 0924 trial.

[^6]: IMRT = intensity-modulated radiotherapy, VMAT = volumetric-modulated arc therapy, GI = gastrointestinal, GU = genitourinary.
